Thema: Presse: Nanopartikel-Therapie geplant
Presse: Nanopartikel-Therapie geplant
Tanja[a]
03.07.2002 00:30:09
Monday July 01, 2002
SOURCE: Advectus Life Sciences Inc.
Advectus Life Sciences Inc. - Pre-clinical brain cancer testing underway
Advectus Life Sciences Inc. announced today that pre-clinical testing of its patented nanoparticle based technology (Nanocure(TM)) has commenced at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure(TM) formulation P80DOX- NP on rodent brain metastases arising from lung carcinoma (2), breast carcinoma, melanoma, renal cell carcinoma, and colon carcinoma.
P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The above study design will be a randomized, placebo- controlled study measuring survival as a surrogate for intracranial tumor progression/regression. Successful demonstration of an antitumor effect will serve as a basis for a clinical trial using P80DOX-NP to treat the large group of patients with brain metastases. The study is designed to lead into Phase I Clinical Trials.
The mission of the University of North Carolina Brain Tumor Center at Chapel Hill is to lead the fight against brain tumors by providing patients with access to the best and most current therapies. UNC - CH collaborates closely with other brain tumor centers to find new treatments and make those new treatments available to all patients as soon as possible. UNC-CH welcomes the opportunity to work with colleagues at other institutions in order to advance the battle against brain tumors.
Advectus Life Sciences Inc. is a development stage company focused on the development and commercialization of a patented process using nanotechnology for the delivery of approved cancer fighting drugs across the blood-brain barrier for the treatment of brain tumors.
SOURCE: Advectus Life Sciences Inc.
Advectus Life Sciences Inc. - Pre-clinical brain cancer testing underway
Advectus Life Sciences Inc. announced today that pre-clinical testing of its patented nanoparticle based technology (Nanocure(TM)) has commenced at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure(TM) formulation P80DOX- NP on rodent brain metastases arising from lung carcinoma (2), breast carcinoma, melanoma, renal cell carcinoma, and colon carcinoma.
P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The above study design will be a randomized, placebo- controlled study measuring survival as a surrogate for intracranial tumor progression/regression. Successful demonstration of an antitumor effect will serve as a basis for a clinical trial using P80DOX-NP to treat the large group of patients with brain metastases. The study is designed to lead into Phase I Clinical Trials.
The mission of the University of North Carolina Brain Tumor Center at Chapel Hill is to lead the fight against brain tumors by providing patients with access to the best and most current therapies. UNC - CH collaborates closely with other brain tumor centers to find new treatments and make those new treatments available to all patients as soon as possible. UNC-CH welcomes the opportunity to work with colleagues at other institutions in order to advance the battle against brain tumors.
Advectus Life Sciences Inc. is a development stage company focused on the development and commercialization of a patented process using nanotechnology for the delivery of approved cancer fighting drugs across the blood-brain barrier for the treatment of brain tumors.
Tanja[a]
